2,405 material Form 8-K filings that 2,035 companies we cover made with the SEC in November 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 1,081 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
EVgo reported third quarter 2026 results, with total revenue down 1% year-over-year while charging network revenue rose 29%. The net loss widened to $49.2 million, and the company updated its full-year 2026 guidance. The board also received a non-binding, unsolicited proposal from LS Power to acquire the shares it does not own for $2.00 per share in cash, which could affect shareholders if pursued.
Total Q3 2026 revenue was $91.4 million, down 1% from $92.3 million, while charging network revenue rose 29% to $71.8 million.
Q3 2026 net loss was $49.2 million, compared with $28.4 million in Q3 2025; adjusted EBITDA loss narrowed to $3.5 million from $5.0 million.
Updated 2026 guidance: total revenue of $375 million to $400 million and adjusted EBITDA loss of $15 million to $30 million.
On November 2, LS Power Equity Advisors proposed to acquire EVgo's Class A shares not already owned by LS Power for $2.00 per share in cash; a special committee of independent directors is reviewing it.
TEN Holdings reported third-quarter 2026 revenue of $640,000, up 17.9% from a year earlier, but its net loss rose 87.9% to $3,734,000. The loss reflects a $1.8 million write-off of previously capitalized service contracts and about $0.5 million in legal expenses, which the company calls non-recurring. Shareholders also face a change in finance leadership, as Ian M. Lawson became interim chief financial officer effective September 30, 2026.
Revenue was $640,000 versus $543,000 a year earlier; gross margin fell to 59.2% from 74.6%.
Net loss was $3,734,000, or $(0.31) per share, compared with $1,987,000, or $(0.84) per share, in the third quarter of 2025.
The company cited a $1.8 million write-off of capitalized service contracts and about $0.5 million in legal expenses.
Ian M. Lawson was appointed interim chief financial officer, effective September 30, 2026.
bioAffinity Technologies reported third-quarter 2026 revenue of approximately $1.1 million, down from approximately $1.4 million a year earlier, which it attributed to lower reimbursement per CyPath Lung test and a slight decline in cases at its Precision Pathology Laboratory Services subsidiary. The net loss widened to approximately $5.3 million from $5.1 million, as the operating loss grew to approximately $3.5 million from $2.3 million, and cash fell to approximately $2.6 million at September 30, 2026, which matters to shareholders given the company's continuing losses.
Q3 2026 revenue was approximately $1.1 million versus approximately $1.4 million in Q3 2025; nine-month CyPath Lung testing revenue rose 79% to approximately $1.1 million.
Q3 net loss was approximately $5.3 million versus $5.1 million; loss from operations was approximately $3.5 million versus $2.3 million.
Cash and cash equivalents were approximately $2.6 million at September 30, 2026, down from $6.4 million at December 31, 2025; a financing after quarter-end generated approximately $4.0 million in gross proceeds.
Sidus Space's audit committee concluded that its audited 2024 and 2025 annual reports and its 2026 quarterly reports for March 31 and June 30 should no longer be relied upon. The company expects the restatements to increase net loss for 2024 and for the first half of 2026, decrease net loss for 2025, and reduce stockholders' equity in every affected period, and it expects to report material weaknesses in internal controls.
Restatement covers the 2024 and 2025 annual reports and the Q1 and Q2 2026 quarterly reports; the 2024 and 2025 10-Ks were filed March 31, 2025 and April 1, 2026.
Net loss expected to increase by about $12.5 million for 2024 and about $4.1 million for the six months ended June 30, 2026; net loss expected to decrease by about $5.5 million for 2025.
Total stockholders' equity expected to decrease by about $15.0 million as of June 30, 2026, compared with amounts originally reported.
Main cause is warrant classification: 3,409,946 warrants issued December 17, 2024 should have been recorded as liabilities; the company also cited a $4.0 million impairment on its LS-2 satellite.
Quoin Pharmaceuticals reported a net loss of $4.9 million for the quarter ended September 30, 2026, up from $3.9 million a year earlier, and a nine-month net loss of $15.2 million versus $11.5 million. The company said it had about $33.2 million in cash, cash equivalents and marketable securities at quarter end, and it highlighted positive interim Netherton Syndrome data and new regulatory designations. Shareholders see a wider loss alongside clinical and regulatory progress.
Q3 2026 net loss was approximately $4.9 million, compared with approximately $3.9 million in Q3 2025.
Nine-month 2026 net loss was approximately $15.2 million, compared with approximately $11.5 million for the same period in 2025.
Cash, cash equivalents and marketable securities were approximately $33.2 million as of September 30, 2026.
Up to $50.0 million private placement was announced August 28, 2026, with approximately $30.8 million in initial upfront funding.
Greif reported fourth-quarter and fiscal 2026 results for the year ended September 30, 2026. Full-year net income rose to $261.5 million, and Adjusted EBITDA rose 11.7%, while fourth-quarter Adjusted EBITDA fell 3.1% to $163.0 million and Adjusted free cash flow of $279.3 million was below the company's most recent guidance range. The company also gave fiscal 2027 low-end guidance of $645 million Adjusted EBITDA and $290 million Adjusted free cash flow.
Fiscal 2026 net income was $261.5 million, or $4.54 per diluted Class A share, versus $31.6 million, or $0.55, a year earlier.
Fourth-quarter net loss narrowed to $6.5 million, or $0.11 per diluted Class A share, from a net loss of $24.3 million, or $0.42, a year earlier.
Company will close its Sweetwater paperboard mill in Austell, GA, and has achieved $105 million in cumulative run-rate cost savings, with a new target of $150 million by the end of fiscal 2027.
Fiscal 2027 low-end guidance: Adjusted EBITDA of $645 million and Adjusted free cash flow of $290 million.
CPS Technologies reported fiscal third-quarter 2026 revenue of $8.9 million, up from $8.8 million a year earlier, with gross margin of 20.9% versus 17.1%. For the nine months, the company posted an operating loss of $423,415 compared with operating income of $542,659 a year earlier, and it signed a lease for an 80,000-square-foot facility in Attleboro, Massachusetts.
Q3 revenue of $8.9 million versus $8.8 million in the prior-year quarter
Q3 gross profit of $1.9 million, or 20.9% of revenue, versus 17.1% a year earlier
Q3 operating income of $357,747 versus $276,082; nine-month operating result was a loss of $423,415 versus income of $542,659
Company signed a long-term lease for an 80,000-square-foot facility in Attleboro, Massachusetts, about twice its current size
Hyster-Yale reported third-quarter 2026 revenue of $827 million, up from $813 million in the second quarter, and narrowed its operating loss to $9 million from $18 million. The company said it expects Q4 2026 revenue to grow sequentially on higher shipments, but tariff-related costs remain elevated and the company plans new cost-reduction programs targeting at least $100 million at maturity in 2029.
Q3 2026 revenue was $827 million versus $813 million in Q2 2026; net loss narrowed to $15 million from $32 million
Operating loss was $9 million in Q3 2026 versus an operating profit of $2.3 million in Q3 2025
Company expects Q4 2026 bookings to exceed Q4 2025 and Q3 2026, with sequential revenue growth
New programs targeting at least $100 million of cost reductions and mitigations at maturity, expected in 2029
BCP Investment Corporation postponed the release of its third quarter 2026 financial results and the related conference call, which were originally scheduled for November 5 and November 6, 2026. The company said the delay gives management more time to finalize financial disclosures, regulatory filings and structural terms tied to a potential strategic initiative, and that there is no assurance this will lead to a definitive agreement or transaction.
Q3 2026 results release and conference call postponed from November 5 and November 6, 2026
Delay tied to finalizing disclosures, regulatory filings and structural terms of a potential strategic initiative
Company states the delay is not related to any accounting, financial or regulatory matters
New call date and dial-in details to be issued by separate press release in the coming days
FB Bancorp reported third-quarter 2026 net income of $466 thousand, down from $1.1 million a year earlier, as non-interest expenses rose and net interest margin fell to 4.30% from 4.65%. Nine-month net income was $515 thousand versus $2.7 million, including a $1.1 million loss from discontinued mortgage banking operations. Shareholders face lower earnings and a commercial loan of approximately $19.8 million now classified as substandard.
Q3 2026 net income was $466 thousand versus $1.1 million in Q3 2025; continuing operations EPS was $0.03 versus $0.06.
Nine-month 2026 net income was $515 thousand, including a $1.1 million loss from discontinued operations, versus $2.7 million a year earlier.
Non-interest expenses rose $390 thousand, or 3.33%, in Q3 2026 year over year, with $686 thousand of stock-based compensation.
A commercial loan with a principal balance of approximately $19.8 million was classified substandard after two co-borrower entities filed for Chapter 11 in June 2026; no specific allowance was recorded.
Biglari Holdings reported third-quarter 2026 net earnings of $1.0 million, compared with a net loss of $5.3 million a year earlier. Pre-tax operating earnings rose to $9.9 million from $6.9 million, though the company said its investment gains and losses also affect reported results.
Q3 2026 pre-tax operating earnings were $9,874 thousand, up from $6,854 thousand in Q3 2025.
Nine-month 2026 net earnings were $26,409 thousand, up from $12,365 thousand in the same period of 2025.
Nine-month 2026 pre-tax operating earnings were $12,007 thousand, down from $20,521 thousand a year earlier.
Steak n Shake same-store sales rose 18.2% in Q3 2026 for domestic company-operated and franchise-partner-operated restaurants.
Star Holdings reported a third-quarter net loss attributable to common shareholders of $45.1 million, or $3.74 per share, for the quarter ended September 30, 2026. The loss reflects a non-cash mark-to-market adjustment of $53.1 million on its roughly 13.5 million Safehold (SAFE) shares, which reduced per-share earnings by $4.40. The company also raised cash through asset sales and cut its margin loan balance roughly in half, which matters to shareholders because the company says it plans to realize value mainly through asset sales and active asset management.
Q3 2026 net loss attributable to common shareholders: $45.1 million, or $3.74 per share
Non-cash SAFE adjustment of $53.1 million reduced earnings per share by $4.40
Sold municipal debt securities portfolio for $50.2 million, with a $4.5 million gain
Sold Coney Island land parcel for $20.0 million with a $4.7 million profit; margin loan reduced from $94.5 million to $46.5 million
Kestrel Group reported a third-quarter 2026 net loss of $16.4 million, or $2.09 per share, on total revenues of $4.8 million. Program Services fee income rose 203% year over year to $2.9 million, while the Legacy Reinsurance segment posted a $6.4 million underwriting loss. Management is targeting about $5 million in run-rate expense savings over the next year.
Q3 2026 net loss of $16.4 million, or $2.09 per share; total revenues of $4.8 million
Program Services fee income of $2.9 million, up 203% year over year; premium produced of $121.2 million, up 132%
Legacy Reinsurance segment underwriting loss of $6.4 million, including a $6.5 million loss in the Diversified business
Targeting approximately $5 million in run-rate expense savings over the next twelve months
DTE Energy Company furnished unaudited financial statements for its indirect subsidiary, DTE Gas Company, for the quarter ended September 30, 2026. DTE Gas reported a net loss of $29 million for the third quarter and net income of $176 million for the first nine months of 2026. These results provide transparency into the operating performance and financial condition of the utility subsidiary for shareholders.
DTE Gas reported operating revenues of $211 million for the third quarter ended September 30, 2026, compared to $207 million for the same period in 2025.
Net loss for the third quarter of 2026 was $29 million, improving from a net loss of $36 million in the third quarter of 2025.
For the nine months ended September 30, 2026, net income was $176 million, compared to $175 million for the first nine months of 2025.
Entera Bio reported a third-quarter 2026 net loss of $15.6 million, or $0.11 per share, up from $3.2 million, or $0.07 per share, a year earlier. The company reported no revenue in either period, and the filing attributes the increase mainly to a $7.5 million non-cash fair value remeasurement of pre-funded warrants. Shareholders also got an update that the first clinical site for the EB613 Phase 3 osteoporosis study is expected to be activated in late 2026, with cash of $265.9 million as of September 30, 2026.
Net loss was $15.6 million for the three months ended September 30, 2026, compared with $3.2 million a year earlier.
The loss increase was primarily driven by a $7.5 million non-cash fair value remeasurement of pre-funded warrants.
Research and development expenses rose to $4.9 million from $1.6 million, mainly for EB613 Phase 3 start-up and the OPKO collaboration.
Cash and cash equivalents were $265.9 million as of September 30, 2026, following a July 2026 private placement with gross proceeds of approximately $275.0 million.
Global Self Storage reported third-quarter 2026 results for the period ended September 30, 2026. Revenue rose 0.6% to $3.2 million and FFO and AFFO grew, but net income fell 16.0% to $417,000 and same-store occupancy slipped to 92.9% from 93.2% a year earlier. The company maintained its $0.0725 quarterly dividend and reported capital resources of about $24.3 million.
Total revenues rose 0.6% to $3.2 million; net income fell 16.0% to $417,000, or $0.04 per diluted share.
FFO rose 5.8% to $1.1 million ($0.09 per diluted share) and AFFO rose 4.7% to $1.1 million ($0.10 per diluted share); both are non-GAAP measures.
Same-store NOI fell 0.6% to $2.0 million, with cost of operations up 2.5% to $1.3 million.
Same-store occupancy was 92.9% as of September 30, 2026, versus 93.2% a year earlier; the quarterly dividend stayed at $0.0725 per share.
Ring Energy reported third-quarter 2026 results on November 5, 2026, with revenue down about 2% from the second quarter to $102.3 million, mainly on lower realized oil prices. The company posted a net loss of $16.6 million, or $0.06 per diluted share, compared with net income of $64.8 million in the prior quarter, which included a $41.0 million unrealized derivative loss this quarter, while adjusted net income rose 14% to $27.3 million.
Revenue $102.3 million, down about 2% from $104.7 million in Q2 2026; realized oil price $83.72 per barrel, down about 12%
Net loss $16.6 million ($0.06 per diluted share) versus net income $64.8 million in Q2 2026; includes a $41.0 million unrealized derivative loss
Adjusted net income $27.3 million ($0.10 per diluted share), up 14%; adjusted EBITDA $57.1 million, up 5%
Revolving credit facility borrowings reduced by $10.0 million to $350.0 million at September 30, 2026; Q4 2026 oil guidance 12,900 to 13,500 Bo/d
U.S. Physical Therapy reported third-quarter 2026 net revenue of $223 million, up 13% year over year, but posted a loss of $1.04 per share, compared with earnings of $0.48 per share a year earlier, mainly due to a non-cash contingent earn-out charge and noncontrolling interest effects described by the company. Management reaffirmed 2026 adjusted EBITDA guidance of $102 million to $106 million and declared a quarterly dividend of $0.46 per share.
Q3 2026 net revenue was $223 million, up 13% from Q3 2025; adjusted EBITDA was $28 million versus $24 million.
Q3 2026 loss per share was $1.04 versus earnings of $0.48 per share; adjusted earnings per share was $0.80 versus $0.66.
Full-year 2026 adjusted EBITDA guidance of $102 million to $106 million was reaffirmed.
Quarterly dividend of $0.46 is payable December 11, 2026, to holders of record on November 16, 2026.
NI Holdings reported third-quarter 2026 net income of $5.5 million, or $0.27 per basic share, compared with a net loss of $1.7 million, or $(0.08) per share, a year earlier. The improvement came mainly from a lower combined ratio, but gross premiums written fell 7.2% as the company continues to exit the Non-Standard Auto segment, which matters to shareholders because premium volume is shrinking.
Net income was $5.5 million for the quarter versus a $1.7 million loss in Q3 2025; nine-month net income was $18.2 million versus a $7.3 million loss.
Combined ratio improved to 93.6% from 109.1%, driven mainly by favorable prior-year loss reserve development in Non-Standard Auto.
Gross premiums written fell 7.2% to $54.3 million and net premiums earned fell 8.6% to $65.8 million; Non-Standard Auto premiums declined 100.2%.
Net investment income was $2.7 million, down 10.7%, as maturities and sales funded operating cash needs in Non-Standard Auto.
Hawaiian Electric Industries reported third quarter 2026 GAAP net income of $35 million, or $0.20 per diluted share, up from $31 million, or $0.18, a year earlier. Non-GAAP Core net income fell to $23 million, or $0.13 per share, from $33 million, or $0.19, as the company absorbed $14 million of storm costs and a $51 million Pacific Current impairment, offset in GAAP results by gains tied to its American Savings Bank stake.
Total third quarter revenues were $1.01 billion, compared with $791 million in the third quarter of 2025.
GAAP diluted EPS was $0.20 versus $0.18; Core diluted EPS was $0.13 versus $0.19.
The quarter included $64 million of pre-tax gains related to HEI's American Savings Bank investment and a non-cash $51 million pre-tax asset impairment at Pacific Current.
Hawaiian Electric recorded $14 million of incremental pre-tax storm costs for August and September, and its Core net income was $28 million versus $40 million a year earlier.
Gogo reported third quarter 2026 revenue of $213.2 million, down 5% from a year earlier, and a net loss of $3.2 million, compared with a $1.9 million loss in the same period of 2025. The company reiterated its 2026 guidance and said it amended and extended its roughly $600 million Term Loan B to October 2030, with $75 million in principal repayments committed through 2027.
Total revenue of $213.2 million, down 5% year over year; Military/Government service revenue rose 36% to $37.2 million
Net loss of $3.2 million (diluted loss of $0.02 per share) versus a $1.9 million loss in Q3 2025; Adjusted EBITDA of $41.0 million, down 27%
2026 guidance reiterated: total revenue of $870 million to $895 million and Adjusted EBITDA of $175 million to $185 million
Term Loan B extended to October 2030, with $30 million to be repaid by December 31, 2026 and $20 million more by December 31, 2027
BOK Financial furnished a November 2026 investor presentation summarizing its third-quarter 2026 results. Net income was $159.9 million, or $2.64 per diluted share, down from $176.5 million, or $2.92, in the second quarter but up from $140.9 million, or $2.22, a year earlier. The presentation also shows the 2026 full-year outlook as of October 20, 2026, which shareholders can compare with the company's prior guidance.
Q3 2026 net income was $159.9 million, or $2.64 per diluted share, versus $176.5 million, or $2.92, in Q2 2026 and $140.9 million, or $2.22, in Q3 2025.
Q2 2026 results included a net gain from the exchange of Visa B shares and a loss from repositioning the available-for-sale securities portfolio; excluding these, Q2 net income would have been $156.5 million, or $2.59 per diluted share.
Net interest margin rose 9 basis points to 3.00%, and period-end loans grew $646 million, or 2.4%, to $27.7 billion.
The 2026 outlook as of October 20, 2026 shows net interest income of $1.43 billion to $1.44 billion and a provision expense below $10 million.
York Water reported third quarter 2026 operating revenues of $24,333,000, up $3,972,000 from a year earlier, and net income of $7,809,000, up $1,608,000. Nine-month revenues rose to $67,922,000 and net income to $20,238,000, both higher than in the same period of 2025, mainly due to rate increases effective March 1, 2026. Both headline measures improved, which points to stronger results for shareholders.
Q3 2026 operating revenues $24,333,000 vs. $20,361,000 in Q3 2025; net income $7,809,000 vs. $6,201,000
Q3 2026 basic and diluted EPS $0.48, up from $0.43 a year earlier
Company estimates an additional $11.8 million of 2026 investment, excluding acquisitions
OneMedNet said it expects preliminary third-quarter 2026 revenue of about $1 million, up 242% from the prior quarter and 465% from the year-earlier quarter. It also guided to fourth-quarter 2026 revenue of $12 million to $14 million, pending customer acceptance of delivered data by quarter-end. The third-quarter figures remain preliminary and may change before the Form 10-Q, expected by November 16, 2026.
Preliminary Q3 2026 revenue of about $1 million for the quarter ended September 30, 2026, up 242% from the prior quarter and 465% from Q3 2025.
Q4 2026 revenue guidance of about $12 million to $14 million, pending customer acceptance of delivered data by quarter-end.
Q3 results are preliminary and subject to adjustment; the Form 10-Q is expected by November 16, 2026.
National HealthCare Corporation reported third-quarter 2026 net operating revenues of $407,971,000, up 6.6%, and adjusted net income of $28,154,000, up 13.8%. GAAP net income attributable to NHC fell to $13,637,000 from $39,239,000, and the company tied the adjusted gain mainly to 2026 facility acquisitions.
Net operating revenues were $407,971,000 for the quarter ended September 30, 2026, versus $382,661,000 a year earlier.
GAAP diluted EPS was $0.85 versus $2.50; adjusted diluted EPS was $1.76 versus $1.58.
Adjusted net income rose to $28,154,000 from $24,744,000, driven by the June 1, 2026 acquisition of five skilled nursing facilities and the July 1, 2026 acquisition of real estate from National Health Investors.
The GAAP decline reflects a $17,599,000 unrealized loss on marketable equity securities in the quarter, which the company excludes from adjusted results.
Minerva Neurosciences reported GAAP net income of $100.7 million for the quarter ended September 30, 2026, compared with a net loss of $2.7 million a year earlier. The company said the result was driven by a $109.6 million non-cash gain from changes in the fair value of its warrant liability, and excluding that gain and stock-based compensation, its adjusted net loss widened to $5.6 million from $2.5 million. For shareholders, the operating loss grew as research and development and general and administrative spending rose, and cash and equivalents fell to about $77.0 million.
GAAP net income of $100.7 million, or $1.94 per basic share and $(0.19) per diluted share, for the three months ended September 30, 2026, versus a net loss of $2.7 million a year earlier.
Non-cash warrant liability gain of $109.6 million; adjusted net loss was $5.6 million versus $2.5 million in the prior-year quarter.
R&D expense was $5.2 million versus $0.9 million, and G&A expense was $4.3 million versus $1.9 million.
Cash, cash equivalents, marketable securities and restricted cash were about $77.0 million at September 30, 2026, down from $82.4 million at December 31, 2025.
Immunocore reported third-quarter 2026 KIMMTRAK net revenue of $102.2 million, down from $103.7 million a year earlier, and a net loss of $14.2 million ($0.28 per share) versus a $0.2 million loss in Q3 2025. The company attributed the revenue decline mainly to U.S. wholesaler stocking in Q2 2026 and one extra week of U.S. sales in Q3 2025, and said underlying growth was about 10%. Nine-month revenue rose to $324.8 million from $295.5 million, and the nine-month net loss narrowed to $2.1 million from $5.5 million.
Q3 2026 net revenue was $102.2 million, versus $103.7 million in Q3 2025; the company cited about 10% underlying growth after adjusting for U.S. items
Q3 2026 net loss was $14.2 million ($0.28 per share), compared with $0.2 million ($0.00 per share) a year earlier
Nine-month 2026 revenue was $324.8 million, up from $295.5 million; nine-month net loss was $2.1 million ($0.04 per share)
Cash, cash equivalents and marketable securities were $901.3 million at September 30, 2026; the company expects about $120 million in sales-related rebate payments in Q4 2026
United Bancorp (UBCP) reported third-quarter 2026 net income of $1.4 million, or $0.25 per diluted share, down 27.4% from $1.9 million, or $0.34, a year earlier. Management attributed the decline to a $2,953,000 charge-off of a single commercial credit, which raised the quarter's provision for credit losses to $2,421,000. Total revenue rose 15.16% and pre-provision net revenue rose 66.45%, but the one-time loan loss reduced earnings for shareholders.
Q3 2026 net income of $1,401,000 and diluted EPS of $0.25, versus $0.34 in Q3 2025
Nine-month net income of $5,407,000 and diluted EPS of $0.94, versus $0.99 a year earlier
Single commercial borrower charge-off of $2,953,000 drove a Q3 provision for credit losses of $2,421,000
Non-GAAP pre-provision net revenue of $3,490,000 for Q3, up $1,393,000 year over year, including a $560,000 securities gain
Plains reported third-quarter 2026 results on November 6, 2026. Net income attributable to PAA fell to $363 million from $441 million, and diluted net income per common unit turned to a loss of $0.06 from a profit of $0.55, while adjusted EBITDA attributable to PAA rose 6% to $711 million on revenues of $15.2 billion. Management said the company is on track to meet full-year 2026 adjusted EBITDA guidance attributable to PAA of $2.880 billion, plus or minus $50 million, so unitholders see a mixed quarter: the operating measure grew, but reported profit declined.
Net income attributable to PAA was $363 million, down 18% from $441 million a year earlier.
Diluted net loss per common unit was $0.06, compared with earnings of $0.55 per unit in the third quarter of 2025.
Adjusted EBITDA attributable to PAA rose 6% to $711 million; revenues were $15.2 billion versus $11.6 billion.
Full-year 2026 adjusted EBITDA guidance attributable to PAA of $2.880 billion plus or minus $50 million was reaffirmed as on track, and a quarterly distribution of $0.4175 per unit was paid.
Plains All American reported third-quarter 2026 results on November 6, 2026. Revenue and adjusted EBITDA attributable to PAA rose, but net income attributable to PAA fell 18% and the per-unit result turned to a loss of $(0.06), which the company tied in part to a $358 million impact from repurchasing Series A preferred units. Management said it is on track to meet full-year 2026 adjusted EBITDA guidance of $2.880 billion, plus or minus $50 million.
Net income attributable to PAA was $363 million versus $441 million a year earlier; diluted net income/(loss) per common unit was $(0.06) versus $0.55.
Revenues were $15.173 billion versus $11.578 billion, and adjusted EBITDA attributable to PAA was $711 million, up 6%.
Full-year 2026 adjusted EBITDA attributable to PAA guidance of $2.880 billion plus or minus $50 million was reaffirmed as on track.
Distribution declared was $0.4175 per unit, up 10% from $0.3800 a year earlier.
Franklin Templeton announced preliminary fourth quarter and full-year results for the period ended September 30, 2026, reporting a quarterly net income of $380.1 million, or $0.72 per diluted share, alongside $20.8 billion in long-term net inflows. Total assets under management reached $1.795 trillion, reflecting an 8% increase year-over-year.
Preliminary fourth quarter net income was $380.1 million, or $0.72 per diluted share, compared to $117.6 million, or $0.21 per diluted share, in the prior-year period.
Long-term net inflows were $20.8 billion for the quarter ended September 30, 2026, and $84.1 billion for the full fiscal year.
Total assets under management were $1.795 trillion as of September 30, 2026.
The company repurchased 2.5 million shares of its common stock for $86.1 million during the fourth quarter.
DarkHorse Technologies reported third-quarter 2026 revenue of $3.0 million, up from $2.6 million a year earlier, and a net loss of $5.8 million, wider than the $4.2 million loss in the third quarter of 2025 but narrower than the $13.8 million loss in the second quarter of 2026. The company says the revenue gain mainly reflects the Cathedra Bitcoin operations acquired June 1, 2026, and the results have limited comparability with the prior year.
Revenue was $3.0 million in Q3 2026, versus $2.5 million in Q2 2026 and $2.6 million in Q3 2025.
Net loss was $5.8 million, or $0.65 per share, versus $4.2 million, or $1.49 per share, in Q3 2025.
Cash and cash equivalents were $8.8 million at September 30, 2026, up from $2.8 million at June 30, 2026.
Contracted power roughly doubled to about 100 MW after a 50 MW contract with Hopkinsville Electric System signed September 30, 2026.
CG Oncology reported a third-quarter 2026 net loss of $56.9 million, or $(0.64) per share, up from $43.8 million, or $(0.57) per share, a year earlier. Total revenue was $1.6 million, down from $1.7 million, while research and development expenses rose to $39.2 million from $27.9 million. Cash, cash equivalents and marketable securities were $984.5 million at September 30, 2026, which the company expects will fund operations through 2029.
Net loss of $56.9 million, or $(0.64) per share, for the quarter ended September 30, 2026, versus $43.8 million, or $(0.57) per share, a year earlier
Total revenue of $1.6 million, compared with $1.7 million in the prior-year quarter
Research and development expenses of $39.2 million, up from $27.9 million, mainly due to higher clinical trial costs and headcount-related compensation
PIVOT-006 Phase 3 topline data expected November 2026; BLA completion for BCG-unresponsive NMIBC expected in Q4 2026
Tredegar reported a third-quarter 2026 net loss from continuing operations of $2.8 million, or $0.08 per diluted share, compared with net income of $7.1 million, or $0.20 per share, a year earlier. Management said results were not where it wants them to be, citing lower building and construction demand at Bonnell Aluminum and weaker Surface Protection demand at High Performance Films. The results are a sharp drop in profitability for shareholders, and the filing gives no updated full-year guidance.
Q3 2026 net loss from continuing operations of $2.8 million, or $0.08 per diluted share, vs. net income of $7.1 million, or $0.20 per share, in Q3 2025
Q3 2026 Consolidated EBITDA from ongoing operations of $4.1 million, vs. $18.1 million in Q3 2025
Aluminum Extrusions Q3 2026 EBITDA from ongoing operations of $2.5 million, vs. $16.8 million in Q3 2025; sales volume fell 11.6%
Net debt rose to $32.7 million at September 30, 2026, from $28.4 million at December 31, 2025
Global Partners LP reported third-quarter 2026 net income of $52.4 million, or $1.26 per diluted common unit, compared with $29.0 million, or $0.66 per unit, a year earlier, while sales rose to $6.7 billion from $4.7 billion. The company said stronger Wholesale results more than offset lower retail fuel volumes, and it declared a $0.7850 per unit distribution payable November 13, 2026. The filing also says the credit agreement was extended to October 16, 2031.
Diluted earnings per common unit were $1.26 versus $0.66; net income was $52.4 million versus $29.0 million.
Adjusted EBITDA was $122.9 million versus $98.8 million; distributable cash flow was $70.1 million versus $53.0 million.
Wholesale product margin rose to $111.4 million from $78.0 million, while GDSO product margin fell to $210.6 million from $218.9 million, and GDSO gasoline volume was 361.3 million gallons versus 390.8 million.
Distribution of $0.7850 per unit is payable November 13, 2026 to holders of record on November 9, 2026; the credit facility maturity was extended to October 16, 2031.
Protara Therapeutics reported third quarter 2026 results, with a net loss of $21.7 million, or $0.35 per share, compared with a net loss of $13.3 million, or $0.31 per share, a year earlier. Research and development expenses rose to $16.8 million from $9.6 million, and the company said cash, cash equivalents and marketable debt securities of $143.1 million should fund operations into 2028.
Q3 2026 net loss of $21.7 million ($0.35 per share) vs. $13.3 million ($0.31 per share) in Q3 2025
R&D expenses rose to $16.8 million from $9.6 million, mainly from higher clinical trial costs of $4.4 million
Cash and marketable debt securities totaled $143.1 million as of September 30, 2026
On November 4, 2026, the company agreed to buy TARA-002 manufacturing-related assets from Novex Innovations for $8.75 million
Calumet reported third-quarter 2026 results, with sales of $1.68 billion, up from $1.08 billion a year earlier. Net income fell to $273.3 million from $313.4 million, and basic earnings per share were $2.91 versus $3.61, after non-cash derivative and RINs-related charges. Adjusted EBITDA rose to $322.0 million from $69.6 million, and the company said it has retired about $265 million of debt since July.
Q3 2026 sales of $1.68 billion vs. $1.08 billion in Q3 2025; net income of $273.3 million vs. $313.4 million
Basic EPS of $2.91 vs. $3.61 a year earlier; net income attributable to common shareholders of $256.4 million
Adjusted EBITDA of $322.0 million vs. $69.6 million; Adjusted EBITDA with Tax Attributes of $347.2 million vs. $92.5 million
Non-cash items included a $113.8 million unrealized derivatives loss and $176.7 million of RINs-related items; $150 million of 2028 Notes were redeemed on October 25, 2026
Georgia Banking Company filed an investor presentation with its third-quarter 2026 results, its first full quarter of combined operations with Tandem Bancorp, which closed June 1, 2026. Net interest income rose 8.0% from the second quarter to $31.4 million, while noninterest income fell 13.8% to $2.8 million and net interest margin declined to 4.17%.
Diluted EPS of $0.57 and operating EPS of $0.74 for the quarter; ROTCE 9.70% and operating ROTCE 12.41%
Net interest income $31.4 million, up 8.0% from 2Q26; NIM down 14 basis points, which the company attributed to higher cost of refinanced subordinated debt
Noninterest income $2.8 million, down 13.8% from 2Q26, due to lower retail mortgage originations
CET1 ratio 10.59% at quarter end, up from 10.29% in 2Q26; management plans to use the presentation in investor meetings beginning November 9, 2026
Dauch reported third quarter 2026 results with sales of $2.91 billion, up from $1.51 billion a year earlier, mainly because of the Dowlais acquisition. The company swung to a net loss attributable to Dauch of $45.3 million, or $(0.19) per share, compared with net income of $9.2 million, or $0.07 per share, a year earlier. It raised its full-year sales outlook but lowered its full-year Adjusted EBITDA range, so the results and guidance point in different directions for shareholders.
Third quarter sales were $2.91 billion versus $1.51 billion in Q3 2025; the Dowlais acquisition was the primary driver of year-over-year changes.
Net loss attributable to Dauch was $45.3 million, or $(0.19) per share, versus net income of $9.2 million, or $0.07 per share, in Q3 2025.
Adjusted EBITDA was $358.5 million, or 12.3% of sales, versus $195.7 million, or 13.0% of sales, a year earlier.
Full-year 2026 Adjusted EBITDA outlook was lowered to $1.35–$1.375 billion from $1.36–$1.425 billion, while the sales outlook was raised to $10.8–$10.875 billion from $10.6–$10.8 billion.
Strive reported GAAP net income of $509.0 million for the quarter ended September 30, 2026, compared with losses in the comparable 2025 periods. The filing attributes the result to a $533.7 million net unrealized gain on digital assets, while total revenues were $2.7 million. Shareholders should note the gain is a fair value adjustment on bitcoin, not operating income.
GAAP net income was $509.0 million, or $5.24 per diluted share, for the three months ended September 30, 2026; non-GAAP adjusted net income attributable to common stockholders was $494.6 million, or $5.46 per diluted share.
Net unrealized gain on digital assets was $533.7 million; total operating expenses were $38.7 million.
Strive acquired 8,136 bitcoin in the third quarter and 15,124 bitcoin from October 1 through October 30, 2026.
On October 20, 2026, Strive completed an offering of 7,000,000 SATS shares for net proceeds of approximately $609.0 million; cash and cash equivalents were $490.4 million as of October 30, 2026.
Aligos Therapeutics reported third quarter 2026 results on November 6, 2026, with a net loss of $21.9 million, down from $31.5 million a year earlier, as revenue rose and research and development spending fell to $18.9 million. Cash, cash equivalents and investments of $31.1 million are expected to fund planned operations only into the first quarter of 2027.
Net loss for the three months ended September 30, 2026 was $21.9 million, or $(2.09) per share, versus $31.5 million, or $(3.04) per share, a year earlier.
Revenue from customers was $2.8 million, up from $0.7 million, and licensing revenue was $39 thousand, compared with none in the prior-year quarter.
Cash, cash equivalents and investments totaled $31.1 million at September 30, 2026, down from $77.8 million at December 31, 2025.
Topline data from the Phase 2 B-SUPREME study of pevifoscorvir sodium are expected in late Q3 2027.
PPL reported third-quarter 2026 GAAP earnings of $367 million, or $0.49 per share, compared with $318 million, or $0.43 per share, in the third quarter of 2025. The company also narrowed its full-year 2026 ongoing earnings forecast to a range of $1.92 to $1.96 per share and increased its long-term annual EPS growth target to 7% to 9% through at least 2030, supported by a $25 billion capital investment plan.
Announced third-quarter 2026 reported GAAP earnings of $0.49 per share on net income of $367 million.
Achieved third-quarter ongoing EPS of $0.54 compared to $0.48 in 2025.
Increased long-term annual EPS growth target to 7% to 9% through at least 2030.
Announced a $25 billion capital plan for 2027 to 2030, driving average annual rate base growth of 10%.
TechTarget reported third-quarter 2026 revenue of $119.2 million, down 2.5% from a year earlier, and said it now expects full-year 2026 revenue to be modestly lower than 2025. Its net loss narrowed sharply from the prior year, which included large goodwill impairment charges, but Adjusted EBITDA fell and the company gave a full-year 2026 Adjusted EBITDA range of $80 million to $85 million.
Q3 2026 revenue was $119.2 million, versus $122.3 million in Q3 2025; nine-month revenue was $341.4 million, versus $346.1 million
Q3 2026 net loss was $18.2 million, versus $76.8 million in Q3 2025; Q3 Adjusted EBITDA was $18.6 million, versus $22.6 million
Full-year 2026 Adjusted EBITDA outlook is $80 million to $85 million, with full-year revenue expected to be modestly lower than 2025
Cash was $35.3 million at September 30, 2026, with $120.1 million drawn on a $250 million revolving credit facility
Under Armour reported revenue of $1.24 billion for the quarter ended September 30, 2026, down 7% from a year earlier, while its net loss narrowed to $425 thousand from $18.8 million. The company raised its fiscal 2027 GAAP operating income outlook to $99 million to $119 million, but cut its expected gross margin improvement, which shareholders should weigh against the lower sales.
Q2 net revenues were $1.24 billion, down 6.9% from $1.33 billion; North America fell 7% and international fell 7%.
Q2 GAAP operating income was $15 million, versus $17 million a year earlier; adjusted operating income was $25 million.
Fiscal 2027 GAAP operating income outlook was raised to $99 million to $119 million, from $96 million to $116 million.
Expected gross margin improvement was lowered to 170 to 220 basis points from 220 to 270, citing fuel, freight and foreign exchange costs.
MSG Rangers reported its first quarter results as a standalone company after its October 26, 2026 spin-off from MSG Knicks. Revenue rose 3% to $14.1 million, but the operating loss widened to $23.6 million and the net loss per share was $1.39, versus $0.89 a year earlier.
Revenues of $14.1 million for the quarter ended September 30, 2026, up $0.4 million, or 3%, from $13.7 million
Operating loss of $23.6 million, up $10.7 million from $12.8 million, driven mainly by higher SG&A and direct operating expenses
Net loss of $16.9 million, or $1.39 per share, compared with a net loss of $10.8 million, or $0.89 per share, a year earlier
Net cash used in operating activities was $71.2 million for the quarter, compared with $5.1 million a year earlier
Telephone and Data Systems reported third quarter 2026 total operating revenues of $306.7 million, down from $308.5 million a year earlier, and net income attributable to TDS common shareholders of $29.6 million from continuing operations, compared with $40.2 million. The company lowered TDS Telecom's 2026 revenue, Adjusted OIBDA and Adjusted EBITDA guidance, raised its capital expenditure estimate, and its board approved an incremental $250 million share repurchase authorization.
Q3 2026 diluted EPS from continuing operations was $0.26, versus $0.33 in Q3 2025; total operating revenues were $306.7 million versus $308.5 million.
TDS Telecom 2026 revenue guidance was cut to $990 million to $1,010 million from $1,000 million to $1,025 million; Adjusted OIBDA guidance was cut to $280 million to $300 million from $300 million to $320 million.
TDS Telecom capital expenditure guidance was raised to approximately $750 million from $625 million to $675 million.
The board approved an incremental $250 million share repurchase authorization; TDS repurchased about 6 million shares in the quarter at an average price of $36.65.
MSG Knickerbockers Corp. reported results for the fiscal first quarter ended September 30, 2026, which include the New York Rangers business it spun off on October 26, 2026. Revenues rose 15% to $45.5 million and operating loss narrowed to $25.5 million, but net loss widened to $31.1 million, or $1.29 per share, from $8.8 million, or $0.37 per share, a year earlier. For shareholders, the top-line and operating results improved while the bottom-line loss grew.
Revenues of $45.5 million, up $6.0 million, or 15%, from the prior-year quarter, led by $3.1 million higher league distributions and $2.6 million higher food, beverage and merchandise sales
Operating loss of $25.5 million, improved $2.0 million, or 7%; adjusted operating loss of $20.0 million, improved $0.8 million, or 4%
Net loss of $31.1 million, or $1.29 per share, versus a net loss of $8.8 million, or $0.37 per share, a year earlier
Cash and cash equivalents fell to $40.0 million at September 30, 2026, from $164.5 million at June 30, 2026, after $146.3 million of cash used in operating activities
Sunstone Hotel Investors reported third-quarter 2026 net income attributable to common stockholders of $38.7 million, or $0.21 per diluted share, compared with a net loss of $2.9 million, or $(0.02) per share, a year earlier. The company raised its full-year 2026 guidance, including adjusted FFO per diluted share of $1.00 to $1.03, up from $0.93 to $0.98, and the quarter included a $31.5 million gain on sale of assets. For shareholders, the results and higher outlook reflect stronger hotel demand and continued stock repurchases, which the company says were completed at a discount.
Third-quarter RevPAR rose 11.4% to $235.22; Total RevPAR rose 10.5% to $394.97.
Adjusted FFO per diluted share rose 17.6% to $0.20; Adjusted EBITDAre rose 8.8% to $54.5 million.
2026 guidance raised: net income attributable to common per diluted share now $0.46 to $0.49 (prior $0.37 to $0.42); RevPAR growth now 9.5% to 10.5% (prior 7.0% to 9.0%).
From the start of 2026 through November 5, 2026, the company repurchased $196.9 million of common and preferred stock, with $310.6 million remaining under its authorization.
Array Digital Infrastructure reported third quarter 2026 results, with total operating revenues from continuing operations rising to $53.9 million from $47.1 million a year earlier. Net income attributable to Array shareholders from continuing operations fell to $69.6 million, or $0.81 per diluted share, from $108.8 million, or $1.25 per share, and the company reaffirmed its 2026 guidance, which it left unchanged.
Total operating revenues from continuing operations were $53.9 million, up from $47.1 million in the third quarter of 2025.
Diluted EPS from continuing operations was $0.81, compared with $1.25 a year earlier.
2026 guidance is unchanged: total operating revenues of $205-$215 million, Adjusted OIBDA of $60-$75 million, Adjusted EBITDA of $220-$235 million, and capital expenditures of $25-$35 million.
TDS said on September 1, 2026 that it is no longer pursuing its non-binding proposal to acquire the Array shares it does not own.
Alpha Metallurgical Resources reported a third-quarter 2026 net loss of $9.3 million, or $0.73 per diluted share, down from a $12.3 million loss in the second quarter but up from $5.5 million a year earlier. The company also issued 2027 operational guidance and said it has committed 3.5 million tons of domestic 2027 sales at an average of $135.48 per ton.
Q3 2026 net loss of $9.3 million ($0.73 per share), versus $12.3 million ($0.96 per share) in Q2 2026 and $5.5 million ($0.42 per share) in Q3 2025
Adjusted EBITDA of $29.4 million, up from $25.6 million in Q2 2026 but down from $41.7 million in Q3 2025
2027 guidance: 14.3 million to 15.7 million total tons shipped and cost of coal sales of $104.00 to $110.00 per ton
Stacker reclaimer at Dominion Terminal Associates damaged in a June storm; replacement expected to take a lengthy time, with insurer discussions ongoing
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.